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Abdominal aortic aneurysm (AAA) is a fatal disease defined as an abdominal aortic diameter of 3.0 cm or more,
where the abdominal aorta exceeds the normal diameter by more than 50%. Histopathological changes of AAA
mainly include extracellular matrix (ECM) remodeling at the abdominal aorta wall, but there is lack of specific drugs
to treat AAA. Recent studies have reported that lysosomal cathepsins could induce vascular remodeling and AAA
formation by regulating vascular inflammation, medial smooth muscle cell apoptosis, neovascularization, and
protease expression. Thus, cathepsins are expected to become a new therapeutic target for AAA treatment.
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Abdominal aortic aneurysm (AAA) is a fatal disease in
which the abdominal aorta diameter is more than 50%
its normal diameter, exceeding 3.0 cm [1]. AAA is like a
time bomb in the body because the progressive increase
in aneurysm size eventually leads to aneurysm rupture
and uncontrollable bleeding, resulting in a mortality of
80%. The primary clinical treatments for AAA include
open surgical repair and endovascular therapy, but so far
there are no specific drugs to prevent or reverse AAA
progression. Thus, studying AAA pathogenesis is neces-
sary to explore and identify treatment targets.AAA, a common high-risk vascular disease
With the aging of the Chinese population, dietary
changes, and new testing methods, the prevalence of
AAA has increased dramatically, but there is still no epi-
demiological data regarding AAA in China. According
to published epidemiological data, AAA is the 13th most
common fatal disease in the United States. The preva-
lence of AAA among the US population in those over 65
years old is 8%, and about 25,000 patients undergo AAA
repair annually [2-4].
Current AAA treatments include open surgical re-
pair and endovascular therapy, which mainly targets* Correspondence: qinyanwen@vip.126.com
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reproduction in any medium, provided the oraneurysms greater than 5.5 cm in diameter, or rapidly
growing aneurysms that are at high risk of rupture.
However, AAA screening suggests that more than 90%
of AAAs are small aneurysms less than 5.5 cm in diam-
eter, so limiting the expansion of small-diameter aneu-
rysms has become a priority in the treatment strategy
for AAA [5]. Results from animal experiments and
clinical trials have suggested that doxycycline, roxi-
thromycin [6], statins [7-9], 2,4-thiazolidinedione [10],
β-blockers [11], and angiotensin-converting enzyme
inhibitors [12] can suppress AAA progression, but fur-
ther mechanistic studies and long-term, large-scale
randomized controlled trials are required to verify the
effects of these drugs.
AAA is a complex disease caused by various factors [13].
It is often seen in older men, and the ratio of male and fe-
male patients is about 10:3. Progressive aortic dilatation
and atherosclerosis during aging induces the development
of AAA. Smoking [14-16] is a major risk factor for AAA,
and it may be induced by nicotine in plasma. It is suggested
that Chlamydia pneumoniae [17] and cytomegalovirus in-
fections [18] may also be involved in AAA pathogenesis.
Though AAA and atherosclerosis share some common
environmental and genetic factors, recent studies have
demonstrated that the AAA disease process is independent
of atherosclerosis [19]. Hypertension promotes AAA
formation through artery wall hardening, and there is
evidence of genetic predisposition to AAA.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for AAA
AAA is a chronic degenerative disease that begins with
local injuries at the abdominal aorta wall followed by
subsequent lesions that affect the entire vessel wall.
Histological changes in AAA mainly involve 1) inflam-
matory cell invasion of the aorta, medial thinning, and
adventitial thickening of the aneurysm; 2) decreased
elastin level (from 15-33% to 5-8%) and imbalanced elas-
tin/collagen ratio, resulting in aorta elasticity loss and
vessel dilation; 3) vascular smooth muscle cell (VSMC)
apoptosis in the tunica media that diminishes vessel
repair capacity; and 4) inflammation of the aortic adven-
titia and perivascular tissues, which are accompanied by
angiogenesis. All these changes eventually lead to aortic
wall remodeling, progressive luminal expansion, and
aneurysm rupture [20].
Though the mechanism underlying vascular remodel-
ing during AAA formation has not been fully elucidated,
present studies suggest that AAA pathogenesis is associ-
ated with inflammatory reactions. Any factors that cause
intimal or adventitial injuries can initiate inflammation
and immune reactions. Various immune and stromal
cells, including macrophages, neutrophils, mast cells,
B/T lymphocytes, fibroblasts, and VSMCs, are involved
in AAA development [21,22]. In the early stage of AAA
formation, inflammatory cells recruited at abdominal
aortic wall release various cytokines, chemokines, and
proteases to induce VSMC apoptosis, ECM protein
degradation, vascular cell migration, and angiogenesis.
It is now believed that medial VSMC apoptosis is the
key to AAA development. VSMCs in AAA tissue show
obvious disorganization and an increased apoptotic
index. VSMCs play a dual role in ECM metabolism; its
affects ECM synthesis by secreting tissue inhibitor of
metalloproteinases (TIMP), tropoelastin, and collagen,
and it mediates ECM degradation by secreting cytokines
to recruit inflammatory cells and elevate matrix metallo-
proteinase (MMP) synthesis and secretion.
MMP-activated elastin and collagen degradation is
suggested to be the direct factor underlying vascular
remodeling during AAA development [23]. MMPs can
degrade elastin, the major component of ECM, and the
degradation products are capable of inducing inflamma-
tory cell infiltration, which in turn increases MMP syn-
thesis through a positive feedback loop and changes
aortic wall elasticity, resulting in aortic expansion and
aneurysm formation. MMP-2 and MMP-9 play a domin-
ant role in AAA pathogenesis [24].
Though extensive research has been conducted on AAA
pathogenesis, the use of anti-inflammatory drugs or
MMPs inhibitors to alleviate AAA progression did not
yield satisfactory results in clinical trials [25-27]. However,
other tissue matrix-degrading enzymes, cathepsins, havereceived considerable attention for their role in AAA
pathogenesis [28].
Cathepsins, the key factor in vascular remodeling
during AAA
Cathepsins are a class of lysosomal proteases that be-
come activated in an acidic environment [29]. Human
cathepsins can be assigned into B, C, D, F, G, H, K, L, O,
S, V, W, and X subtypes, most of which are cysteine pro-
teases, with the rest being aspartic acid or serine prote-
ases. Cathepsins can be activated by the hydrolysis of an
inactive zymogen precursor at the low pH found in the
lysosome. AAA risk factors, such as smoking, hyperten-
sion, and atherosclerosis, can all cause vascular endothe-
lial cell damage, which increase lysosomal membrane
permeability and induce cathepsin secretion. The activity
of cathepsins can be modulated by two factors: environ-
mental pH value and the presence of cathepsin endogen-
ous inhibitors (such as cystatin C), which suppress
cathepsin activity through binding its target proteins.
Studies have suggested [30] that inflammatory factors
such as tumor necrosis factor (TNF)-α and interferon
(IFN)-γ can induce the secretion of cathepsins from
vascular endothelial cells, macrophages, and VSMCs.
Nicotine stimulates cathepsin L secretion from pheo-
chromocytoma, and free cholesterol induces cathepsin K
release from macrophages by activating the Toll-like
receptor and p38 mitogen-activated protein kinase [31].
Oxidized low-density lipoprotein (LDL) stimulates ca-
thepsin S expression and secretion from macrophages
[32]. Angiotensin II (AngII)-treated macrophages ex-
hibit increased lysosomal membrane permeability and
rupture and induce cathepsin F expression, secretion,
and activation [33].
The effects of cathepsins in cardiovascular diseases
have raised increasing concern in recent years. Cathep-
sin expression level and activity are significantly elevated
during AAA formation [34,35]. Immunohistochemistry
and western blot demonstrated a lack of cathepsin L in
normal vessels but strong positive signals in AAA tis-
sues. Cathepsin L mRNA levels in AAA lesions exceeded
that in normal aorta tissue by 22%, and cathepsin H pro-
tein levels in AAA lesion was 330% higher than aorta
tissue sampled from patients with artery occlusion. Im-
munofluorescence probes revealed that compared with
occluded artery, the activities of cathepsin B, H, L, and S
in AAA tissues were increased by 376%, 191%, 223%,
and 20%, respectively. Studies also demonstrated that
compared with normal vessels, the expression of each
cathepsin subtype in AAA tissues was significantly in-
creased. In AAA lesions, luminal endothelial cells mainly
expressed cathepsin D, as well as cathepsin B, K, and S,
while neovascular endothelial cells, macrophages, and
VSMCs could express all cathepsin subtypes. It has been
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AAA patient serum is increased by ~30%, and the mag-
nitude of elevation was significantly associated with the
size of the AAA. Other reports described that the ex-
pression and activity of cathepsin D in AAA patients’
serum and plasma were significantly higher than in
healthy controls. In addition, cathepsin expression and
activation is often observed in AAA animal models. Im-
munohistochemistry and immunoblotting conducted in
a mouse AAA model (established by 28-d AngII infusion
in apolipoprotein [ApoE]-/- mice) showed that [37] nor-
mal vessels barely expressed cathepsin S, while AAA tis-
sue had significantly increased cathepsin S expression,
which exceeded that in the normal vessel by 90%. Also,
the expression levels of cathepsin K, S, and C were 5-
fold higher than that in normal vessels. In a 14-d
elastase-infused rat AAA model, increased cathepsin C
expression was observed at an early stage of AAA [38].
Studies of cathepsin knock-out mice confirmed the es-
sential role of cathepsins in AAA pathogenesis (Table 1).
Qin et al. [37] established a cathepsin S/ApoE double
knockout mouse model using AngII infusion, and found
that the cathepsin S-knockout mice showed significantly
reduced AAA incidence (1/8 of that observed in
ApoE-/- mice), and a 47% (0.86 mm) decrease in ab-
dominal aortic diameter [7]. The incidence and diameter
of AAA in elastin-infused cathepsin K [39] or L [40]
knock-out mice were significantly reduced, and these
mice also showed decreased T lymphocyte migration,
neovascularization, MMP expression, and cathepsin
activation. As for elastin-infused cathepsin C-knockout
mice, they can hardly form AAA [41]. Conversely,
cathepsin C/ApoE double knockout mice infused with
AngII exhibited 55% and 50% increases in AAA lesion
size and diameter, respectively [38]. In situ zymography
demonstrated that CaCl2-infused AAA mouse showed
suppressed elastase activaty, enhanced aorta stability,
and reduced vessel damage when treated with serine
protease inhibitor A3, a non-specific inhibitor of
cathepsin G.Table 1 Cysteinyl cathepsins and AAA
Cathepsins Role in AAA
Cathepsin G
inhibition




Decrease T lymphocyte migration, neovascularization,
MMP expression, and cathepsin activation
Cathepsin L
knockout
Lower the number of macrophages and decrease T
lymphocyte migration, neovascularization, MMP
expression, and cathepsin activation
Cathepsin S
knockout
Damage elastin integrity, increase collagen
accumulation, lower the number of macrophagesThe mechanisms and effects of cathepsins in AAA
pathogenesis are not been fully understood. Studies have
demonstrated [42] that cathepsin S-knockout mice have
damaged elastin integrity and increased collagen accu-
mulation at the arterial wall, while small molecule inhib-
itors of cathepsin S suppressed elastase activity by 80%,
suggesting that active cathepsin S could degrade extra-
cellular soluble elastin. Shi et al. [29,40] found that after
knockout of cathepsins S and L, the number of macro-
phages were lowered through reductions in monocyte
chemoattractant protein-1 (MCP-1) and macrophage
migration, thereby alleviating inflammation reactions
during AAA development. By using AngII to treat mac-
rophages of cathepsin S-knockout mice, Pan [43] dem-
onstrated that cathepsin S could modify inflammatory
fibrosis by inducing mitochondrial damage, elevating re-
active oxygen species levels and increasing nuclear factor
kappa-B (NF- κB) activity. By using the selective cathep-
sin S selective inhibitor Compound A to treat ozone-
exposed neutrophils in the bronchoalveolar lavage fluid,
Williams et al. [44] found that inhibiting cathepsin S
could reduce interleukin (IL)-6 and TNF-α levels, thus
alleviating inflammatory reactions. Qin et al. [37] used
the selective cathepsin S Z-FL-COCHO against AngII-
induced VSMC apoptosis, and their results suggested
that inhibiting cathepsin S decreased apoptosis by down-
regulating both the Bax/Bcl-2 ratio and caspase-3 ex-
pression. Cathepsin G can induce neovascularization in
tumor tissues by activating the transforming growth fac-
tor (TGF)-β pathway and enhancing the expression of
vascular endothelial growth factor (VEGF) and MCP-1
[45]. It can also increase MMP expression by promoting
the conversion of MMP-1 zymogen into active MMP-1
[46]. Cathepsin G [47] can promote conversion of Ang I
to Ang II, and it is also capable of generating Ang II
directly from angiotensinogen. Daugherty et al. [48]
demonstrated that apoE-/- mice infused with Ang II had
increased plasma concentrations and pronounced ab-
dominal aortic aneurysms.
Conclusions
In summary, increased cathepsin expression levels and
reduced levels of their inhibitors in human AAA le-
sions suggest a role of these proteases in AAAs. Re-
duced AAA size and incidence in cathepsin-deficient
mice but enlarged aortic size in the absence of their in-
hibitors, demonstrates that these proteases directly
participate in AAA pathogenesis. Although selective
inhibitors for several major AAA cathepsins are avail-
able, none have been tested in experimental AAAs or
in humans. Serum biomarkers have proved useful in
assessing the risk associated with several diseases.
Plasma cathepsin S levels are significantly higher in
AAA patients than in age-matched healthy controls
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correlated with the maximum diameter of the abdom-
inal aorta. Combined serum cathepsin S and hs-CRP
levels are better at indirectly predicting the maximum
diameter and the degree of inflammatory response in
AAA lesions in the clinical setting [49]. This evidence
suggests that cathepsins may be used as a diagnostic
indicator of AAA.
While studies have shown that cathepsins are dir-
ectly involved in AAA pathogenesis, the relationships
between AAA and different cathepsin subtypes, the in-
teractions between cathepsins and other risk factors
for AAA and the effects of cathepsins in different
stages of AAA development remain to be elucidated.
Although the study of cathepsin inhibitors on treating
AAA is limited to pre-clinical research, lysosomal ca-
thepsins as a diagnosis tool and treatment target for
halting AAA development are of particular clinical sig-
nificance and should be paid considerable attention.
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